Germany, France, Italy, and Spain have grow to be the most recent international locations to droop utilizing the vaccine, becoming a member of Ireland, Denmark, Thailand, the Netherlands, Norway, Iceland, Congo, and Bulgaria.
AstraZeneca issued a press release saying that 15 circumstances of DVT and 22 of pulmonary embolism had been reported amongst individuals receiving the vaccine within the United Kingdom and the European Union.
The European Medicines Agency (EMA) stated suspending use of the AstraZeneca vaccine is “a precaution taken within the mild of their nationwide scenario.” But the EMA in addition to the World Health Organization stated knowledge doesn’t present the vaccine precipitated the clots and other people ought to preserve getting vaccinated with it as a result of the profit outweighs the danger.
“Many thousands of people develop blood clots annually in the EU for different reasons. The number of thromboembolic events overall in vaccinated people seems not to be higher than that seen in the general population,” the EMA stated in a statement.
AstraZeneca defended the security of the vaccine.
“Around 17 million people in the EU and UK have now received our vaccine, and the number of cases of blood clots reported in this group is lower than the hundreds of cases that would be expected among the general population,” Ann Taylor, chief medical officer, stated in a news release.
“The nature of the pandemic has led to increased attention in individual cases and we are going beyond the standard practices for safety monitoring of licensed medicines in reporting vaccine events, to ensure public safety.”
AstraZeneca says clinical trials present its vaccine has an efficacy of about 70% in comparison with the 95% and 94% efficacy for the Pfizer and Moderna vaccines, respectively. All three are being utilized in Europe.
The World Health Organization approved the AstraZeneca-University of Oxford vaccine on Feb. 15. That allowed the United Nations to distribute doses to low- and middle-income international locations.
AstraZeneca says it plans to hunt emergency use authorization from the FDA quickly.